The historical rank and industry rank for Henan Lingrui Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:600285'
s EV-to-FCF Range Over the Past 10 Years
Min: -369.39 Med: 10.68 Max: 224.47
Current: 19.22
During the past 13 years, the highest EV-to-FCF of Henan Lingrui Pharmaceutical Co was 224.47. The lowest was -369.39. And the median was 10.68.
SHSE:600285's EV-to-FCF is ranked better than 57.12% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs SHSE:600285: 19.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Henan Lingrui Pharmaceutical Co (SHSE:600285) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Henan Lingrui Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Henan Lingrui Pharmaceutical Co's share price for today is ¥22.66.
Henan Lingrui Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.389.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Henan Lingrui Pharmaceutical Co EV-to-FCF Related Terms
Henan Lingrui Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Henan Lingrui Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henan Lingrui Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Henan Lingrui Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Henan Lingrui Pharmaceutical Co's EV-to-FCF falls into.
Henan Lingrui Pharmaceutical Co's current Enterprise Value is ¥12,425 Mil.
Henan Lingrui Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥646 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co (SHSE:600285) has a EV-to-FCF of 19.22 as of Jul. 13, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. This is 80% above median its historical median of 10.68. According to the industry distribution chart, Henan Lingrui Pharmaceutical Co ranks #241 out of 562 companies in the Drug Manufacturers industry, placing it in the top 42.9%.
Is Henan Lingrui Pharmaceutical Co's EV-to-FCF too high?
Henan Lingrui Pharmaceutical Co's current EV-to-FCF of 19.22 is 80% above median its 10-year median of 10.68. The Drug Manufacturers industry median EV-to-FCF is 20.96. Henan Lingrui Pharmaceutical Co's value of 19.22 is 8.3% below this industry median. Based on the distribution chart, Henan Lingrui Pharmaceutical Co ranks #241 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Henan Lingrui Pharmaceutical Co has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Henan Lingrui Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Henan Lingrui Pharmaceutical Co ranks #241 out of 562 companies for EV-to-FCF. This puts Henan Lingrui Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 20.96. Henan Lingrui Pharmaceutical Co's value of 19.22 is 8.3% below this benchmark. While the company's 10-year median is 10.68 vs. the industry median of 20.96, Henan Lingrui Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Henan Lingrui Pharmaceutical Co's current EV-to-FCF of 19.22 is 8.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henan Lingrui Pharmaceutical Co's current EV-to-FCF is 19.22, which is 80% above median its own 10-year median of 10.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Lingrui Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co (SHSE:600285) is currently considered Fairly Valued. The stock's GF Value™ is ¥24.39, compared to a current price of ¥22.66 — trading 7.1% below its estimated fair value. The current EV-to-FCF is 19.22, which is 80% above median its 10-year median of 10.68 and 8.3% below the Drug Manufacturers industry median of 20.96. Henan Lingrui Pharmaceutical Co's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Henan Lingrui Pharmaceutical Co (SHSE:600285), the current EV-to-FCF is 19.22 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥22.66 is trading 7.1% below its estimated GF Value™ of ¥24.39.
GuruFocus considers Henan Lingrui Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600285:
EV-to-FCF: 19.22 (80% above median its 10-year median of 10.68)
GF Value™: ¥24.39 vs. price of ¥22.66 (7.1% below fair value)
Industry Position: 8.3% below the Drug Manufacturers median (#241 of 562)
No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Lingrui Pharmaceutical Co Business Description
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
97GF Score
Get the complete analysis for SHSE:600285
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600285 has been successfully added to your 
